Granulocyte Colony Stimulating Factor, Peripheral Blood Stem Cells and Bone Marrow Stem Cells for Cardiac Repair After Myocardial Infarction

Shinya Minatoguchi, MD, PhD

Granulocyte colony stimulating factor (G-CSF), which can mobilize bone marrow stem cells into peripheral blood, has been reported to repair cardiac tissues and improve post-infarct left ventricular (LV) remodeling and function.¹⁻³ It has been reported that stromal derived factor-1 (SDF-1) and its receptor chemokine receptor 4 (CXCR4) play important roles in the homing of stem cells,⁴ and G-CSF enhances the SDF-1-CXCR4 axis and results in the mobilization, migration and homing of progenitor cells or stem cells from bone marrow to the infarcted sites.^{5,6} Various mechanisms for the beneficial effects of G-CSF in the infarcted heart have been proposed: regeneration of myocardium,^{1,2} acceleration of the healing process,² protection from apoptosis,³ reduction of myocardial fibrosis,^{2,7} and a direct cardioprotective effect.⁸ Because of these effects, the use of G-CSF to repair the injured myocardium in patients with myocardial infarction has generated keen interest. Some clinical trials have supported the idea that G-CSF could be effective in patients with acute myocardial infarction with late reperfusion,⁹⁻¹¹ while others have not been able to reproduce the beneficial effects observed in experimental models.^{12,13} That is, the results of clinical trials have been controversial,¹⁴ and, if any, the effect is modest. On the other hand, peripheral blood stem cells (PBSCs) or bone marrow stem cells have also been considered to repair cardiac tissues and improve post-infarct LV remodeling and function in animals.¹⁵⁻¹⁷ In clinical trials, there are controversies as to the outcome of cell therapies.¹⁸⁻²⁰ However, meta-analysis of cell-based clinical trials has revealed that intracoronary transplantation of PBSCs or bone marrow-derived stem cells in several recent trials is associated with increases in the LV ejection fraction (LVEF) and a reduction of LV end-systolic volumes, although these effects are modest.²¹

Article p955

Therefore, the results of clinical trials of G-CSF, intracoronary bone marrow stem cells or PBSCs highlight the need for elucidating other methods to achieve better therapeutic outcomes. One such method may be a combination of G-CSF and intracoronary bone marrow stem cells or PBSCs and modifying the administration method. Steinwender et al demonstrated that the combination of G-CSF therapy and a single

transcoronary transplantation of CD34+ cells resulted in a significant increase in global LVEF and regional systolic wall motion after 6 months, but implied there was a high risk of increasing the in-stent restenosis rate.²²

In this issue of the Journal, Gu et al²³ demonstrate that repeated intracoronary infusion of PBSCs plus mobilization of G-CSF may be an effective strategy option for treating patients with refractory congestive heart failure after myocardial infarction. In patients with a recent large myocardial infarction and a lower LVEF, repeated intracoronary infusion of PBSCs plus one dose of G-CSF improved LVEF significantly higher than in the group with a single infusion of PBSC and a G-CSF dose or the group with neither PBSCs nor G-CSF dose. No side effects were observed during the study and they conclude that repeated administration of combined PBSC therapy and G-CSF therapy is safe. Although this is a pilot and small-scale clinical trial, it is the first report of the effect of combining repeated intracoronary infusions of PBSCs and G-CSF on cardiac function and myocardial perfusion in patients with congestive heart failure after myocardial infarction, which is a safe and less invasive method for cardiac repair. Larger scaled, randomized, placebo-controlled clinical trials will be needed to confirm the efficacy of treating patients with refractory congestive heart failure after a recent large myocardial infarction.

References

1. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. *Proc Natl Acad Sci* 2001; **98**: 10344–10349.
2. Minatoguchi S, Takemura G, Chen XH, Wang N, Uno Y, Koda M, et al. Acceleration of healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. *Circulation* 2004; **109**: 2572–2580.
3. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. *Nat Med* 2005; **11**: 305–311.
4. Broxmeyer HE. Chemokines in hematopoiesis. *Curr Opin Hematol* 2008; **15**: 49–58.
5. Misao Y, Takemura G, Arai M, Onogi H, Takahashi T, Minatoguchi S, et al. Importance of recruitment of bone marrow-derived CXCR4+ cells in post-infarct cardiac repair mediated by G-CSF. *Cardiovasc Res* 2006; **71**: 455–465.

The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.

Received February 3, 2011; accepted February 3, 2011; released online March 1, 2011

Department of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan

Mailing address: Shinya Minatoguchi, MD, PhD, Department of Cardiology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan. E-mail: minatos@gifu-u.ac.jp

ISSN-1346-9843 doi:10.1253/circj.CJ-11-0142

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp

6. Zaruba MM, Franz WM. Role of the SDF-1-CXCR4b axis in stem cell-based therapies for ischemic cardiomyopathy. *Expert Opin Biol Ther* 2010; **10**: 321–335.
7. Li Y, Takemura G, Okada H, Miyata S, Esaki M, Maruyama R, et al. Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure. *Lab Invest* 2006; **86**: 32–44.
8. Sumi S, Kobayashi H, Yasuda S, Iwasa M, Yamaki T, Yamada Y, et al. Postconditioning effect of granulocyte colony-stimulating factor is mediated through activation of risk pathway and opening of the mitochondrial KATP channels. *Am J Physiol Heart Circ Physiol* 2010; **299**: H1174–H1182.
9. Ince H, Petzsch M, Kleine HD, Schmidt H, Rehders T, Korber T, et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). *Circulation* 2005; **112**: 3097–3106.
10. Suzuki K, Nagashima K, Arai M, Uno Y, Misao U, Takemura G, et al. Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease: A pilot study. *Circ J* 2006; **70**: 430–437.
11. Takano H, Hasegawa H, Kuwabara Y, Nakayama T, Matsuno K, Miyazaki Y, et al. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. *Int J Cardiol* 2007; **122**: 41–47.
12. ZohInhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: A randomized controlled trial. *JAMA* 2006; **295**: 1003–1010.
13. Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Wintersperger BJ, Werle-Ruedinger AE, et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: Final results from the G-CSF STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. *J Am Coll Cardiol* 2006; **48**: 1712–1721.
14. Shim W, Mehta A, Lim SY, Zhang G, Lim CH, Chua T, et al. G-CSF for stem cell therapy in acute myocardial infarction: Friends or foe? *Cardiovasc Res* 2011; **89**: 20–30.
15. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. *Proc Natl Acad Sci USA* 2005; **102**: 11474–11479.
16. Misao Y, Takemura G, Arai M, Sato S, Suzuki K, Miyata S, et al. Bone marrow-derived myocyte like cells and regulation of repair-related cytokines after bone marrow cell transplantation. *Cardiovasc Res* 2006; **69**: 476–490.
17. Zhang S, Ge J, Zhao L, Qian J, Huang Z, Shen L, et al. Host vascular niche contributes to myocardial repair induced by intracoronary transplantation of bone marrow CD34+ progenitor cells in infarcted swine heart. *Stem Cells* 2007; **25**: 1195–1203.
18. Strauer BE, Brehm M, Zeus T, Kosterling M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. *Circulation* 2002; **106**: e9039–e9040.
19. Tatsumi T, Ashihara E, Yasui T, Matsunaga S, Kido A, Sasada Y, et al. Intracoronary transplantation of non-expanded peripheral blood-derived mononuclear cells promotes improvement of cardiac function in patients with acute myocardial infarction. *Circ J* 2007; **71**: 1199–1207.
20. Choi JH, Choi J, Lee WS, Rhee I, Lee SC, Gwon HC, et al. Lack of additional benefit of intracoronary transplantation of autologous peripheral blood stem cell in patients with acute myocardial infarction. *Circ J* 2007; **71**: 486–494.
21. Reffelmann T, Konemann S, Kloner RA. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair. *J Am Coll Cardiol* 2009; **53**: 305–308.
22. Steinwender C, Hofmann R, Kammler J, Kypta A, Pichler R, Maschek W, et al. Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcatheter transplantation after primary stent implantation for acute myocardial infarction. *Am Heart J* 2006; **151**: 1296.e7–1296.e13.
23. Gu X, Xie Y, Gu J, Sun L, He S, Xu R, et al. Repeated intracoronary infusion of peripheral blood stem cells with G-CSF in patients with refractory ischemic heart failure: A pilot study. *Circ J* 2011; **75**: 955–963.